Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
Citi
Novartis
McKinsey
US Army
Harvard Business School
Argus Health
Queensland Health
Chubb

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022253

« Back to Dashboard

NDA 022253 describes VIMPAT, which is a drug marketed by Ucb Inc and is included in three NDAs. It is available from three suppliers. There is one patent protecting this drug and three Paragraph IV challenges. Additional details are available on the VIMPAT profile page.

The generic ingredient in VIMPAT is lacosamide. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
Summary for 022253
Tradename:VIMPAT
Applicant:Ucb Inc
Ingredient:lacosamide
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 022253
Suppliers and Packaging for NDA: 022253
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIMPAT lacosamide TABLET;ORAL 022253 NDA UCB, Inc. 0131-2470 N 0131-2470-99
VIMPAT lacosamide TABLET;ORAL 022253 NDA UCB, Inc. 0131-2477 N 0131-2477-35

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG
Approval Date:Oct 28, 2008TE:RLD:Yes
Regulatory Exclusivity Expiration:Nov 3, 2020
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:➤ Sign UpPatent Expiration:Mar 17, 2022Product Flag?Substance Flag?YDelist Request?
Patented Use:METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
Patent:➤ Sign UpPatent Expiration:Mar 17, 2022Product Flag?Substance Flag?YDelist Request?
Patented Use:METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER

Expired US Patents for NDA 022253

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-001 Oct 28, 2008 ➤ Sign Up ➤ Sign Up
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-002 Oct 28, 2008 ➤ Sign Up ➤ Sign Up
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-003 Oct 28, 2008 ➤ Sign Up ➤ Sign Up
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-004 Oct 28, 2008 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Express Scripts
Moodys
Harvard Business School
Baxter
Cantor Fitzgerald
Dow
Argus Health
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot